Patents by Inventor Wolfgang Schaefer

Wolfgang Schaefer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20180222981
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: January 24, 2018
    Publication date: August 9, 2018
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20180222993
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
  • Dual FC antigen binding proteins
    Patent number: 9982036
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 29, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • METHOD FOR PRODUCING A CONTACT SPACING CONVERTER AND CONTACT SPACING CONVERTER
    Publication number: 20180120353
    Abstract: A method for producing a contact spacing converter space transformer) which has electrical contacts that form electrical paths and in which a first contact spacing of the contacts is converted into a comparatively different, second contact spacing of the electrical contacts including producing at least one base part from each of at least some of the electrical contacts. At least a section of the base part is produced from plastic. The method subsequently includes metallization of at least the section of the base part that is produced from plastic.
    Type: Application
    Filed: February 15, 2016
    Publication date: May 3, 2018
    Applicant: FEINMETALL GMBH
    Inventors: Christian KÖNIG, Jörg BURGOLD, Gunther BÖHM, Wolfgang SCHÄFER
  • BISPECIFIC ANTIGEN BINDING PROTEINS
    Publication number: 20180079805
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 24, 2017
    Publication date: March 22, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Sabine IMHOF-JUNG, Christian KLEIN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Juergen Michael SCHANZER
  • Bispecific T cell activating antigen binding molecules
    Patent number: 9914776
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: March 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • MONOVALENT ANTIGEN BINDING PROTEINS
    Publication number: 20180037633
    Abstract: The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 12, 2017
    Publication date: February 8, 2018
    Inventors: Birgit BOSSENMAIER, Hubert KETTENBERGER, Christian KLEIN, Klaus-Peter KUENKELE, Joerg Thomas REGULA, Wolfgang SCHAEFER, Manfred SCHWAIGER, Claudio SUSTMANN
  • Electrical contacting device
    Patent number: 9863978
    Abstract: An electrical contacting device for electrical physical contact with a specimen, particularly wafers, taking place in a contacting direction, with at least one conductor substrate which can be electrically connected to a testing device, at least one contact distance transformer and at least one contact head having electrical contact elements, particularly resilient contact elements, preferably serving to compensate different physical contact distances existing in the contacting direction particularly at the contact elements.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: January 9, 2018
    Assignee: FEINMETALL GMBH
    Inventors: Gunther Böhm, Georg Steidle, Wolfgang Schäfer, Achim Weiland
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20170369566
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 23, 2017
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • MULTISPECIFIC ANTIBODIES
    Publication number: 20170369595
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: June 2, 2017
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ULRICH BRINKMANN, WOLFGANG SCHAEFER, KLAUS MAYER
  • MULTISPECIFIC ANTIBODIES
    Publication number: 20170349669
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: May 15, 2017
    Publication date: December 7, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: SABINE IMHOF-JUNG, CHRISTIAN KLEIN, STEFAN KLOSTERMANN, JOERG THOMAS REGULA, WOLFGANG SCHAEFER
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 FOR USE IN THE TREATMENT OF OVARIAN CANCER
    Publication number: 20170306044
    Abstract: Bispecific antibodies against CD3epsilon and ROR1 are useful for use in the treatmentof ovarian cancer.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN kLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1
    Publication number: 20170306018
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN KLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA
    Publication number: 20170306036
    Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3epsilon, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), r aspartic acid (D) (numbering according to Kabat). Also the manufacture and use of said antibody.
    Type: Application
    Filed: August 3, 2015
    Publication date: October 26, 2017
    Applicant: ENGMAB AG
    Inventors: Minh Diem VU, Klaus STREIN, Oliver AST, Marina BACAC, Lydia Jasmin HANISCH, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Samuel MOSER, Ramona MURR, Pablo UMANA, Sabine JUNG-IMHOF, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg REGULA, Wolfgang SCHAEFER
  • BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20170240626
    Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: October 4, 2016
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas
  • HER3/HER2 BISPECIFIC ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3 AND DOMAIN II OF HER2
    Publication number: 20170233490
    Abstract: The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.
    Type: Application
    Filed: November 10, 2016
    Publication date: August 17, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Richard Buick, Stefan Dengl, Michael Gerg, Carmen Peess, Wolfgang Schaefer, Michael Schraeml, Claudio Sustmann
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 9708396
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20170198043
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: October 20, 2016
    Publication date: July 13, 2017
    Applicant: Roche Glycart AG
    Inventors: Johannes Auer, Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Wolfgang Schaefer, Claudio Sustmann, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170190783
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: July 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christianne Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170174786
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: June 22, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Pablo Umana, Sylvia Herter, Christiane Neumann